术后降钙素不可测与甲状腺髓样癌长期无病生存相关:回顾性队列研究结果
该回顾性队列纳入两家三级教学医院的334例甲状腺髓样癌患者,按术后降钙素是否可测分组。中位随访7.7年后,术后降钙素不可测组90.1%无病生存,可测组9.2%无病生存;多因素分析显示术后降钙素不可测是无病生存的独立预后因素(HR=5.33,CI=2.86-9.94;p<0.001)。
要点
- 术后降钙素不可测组141例,中位随访7.7年后90.1%无病生存,无病相关死亡。
- 术后降钙素可测组中9.2%无病生存,32.6%死于疾病相关事件。
- 术后降钙素不可测是无病生存的独立预后因素(HR=5.33,CI=2.86-9.94;p<0.001)。
核心结论
- 术后降钙素不可测是甲状腺髓样癌长期无病生存的强预后标志物,可能有助于制定随访策略。
研究设计与样本
- 回顾性队列研究,收集两家三级教学医院甲状腺髓样癌患者的病历资料,共纳入334例患者,按术后降钙素不可测或可测分为两组。
主要发现
- 术后降钙素不可测组141例,中位随访7.7年(2.1-13.2年)后127例(90.1%)无病生存,14例(9.9%)为持续性生化疾病伴降钙素水平稳定,无患者死于疾病相关事件。
- 术后降钙素可测组中18例(9.2%)达到无病状态,51例(26.6%)为生化疾病,61例(31.6%)为持续性结构性疾病,63例(32.6%)死于疾病相关事件。
- 多因素模型显示术后降钙素不可测是无病生存的独立预后变量(HR=5.33,CI=2.86-9.94;p<0.001)。
临床怎么用
- 原文结论指出术后降钙素不可测是长期无病生存的强预后标志物,可能有助于制定甲状腺髓样癌患者的随访策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Calcitonin measurement is widely used in the diagnosis, prognosis, and follow-up of patients with medullary thyroid carcinoma (MTC). The prognostic value of undetectable postoperative calcitonin (POCal) in long-term disease outcomes remains uncertain. Objective: The aim of this study is to evaluate POCal as a prognostic marker for long-term MTC disease status. Methods: A retrospective cohort study was carried out. We collected data from the medical records of patients with MTC attending two tertiary teaching hospitals. Patients were divided according to POCal into two groups: undetectable (below the detection limit) or detectable. The outcome was determined at the last medical visit and defined as disease free (undetectable calcitonin and no evidence of disease on imaging), persistent disease (detectable calcitonin with or without structural disease), or disease-related death. Results: Three hundred thirty-four MTC patients were included in the study. The mean age at diagnosis was 41.1 ± 18.6 years; 202 patients (60.5%) were women; and 167 patients (50.0%) had sporadic MTC. The median tumor size was 2.0 cm (1.1-3.5 cm); 164 patients (49.1%) had lymph node metastasis and 63 patients (18.9%) had distant metastasis. At the first postoperative evaluation (3-6 months after surgery), 141 patients had undetectable POCal (mean age = 37.9 years, 70.9% women, median tumor size 1.5 cm [0.7-2.5 cm]; 28 [19.9%] had lymph node metastasis and none had distant metastasis). After a median follow-up of 7.7 years (2.1-13.2 years), 127 (90.1%) of these patients were free of disease, whereas 14 (9.9%) had persistent biochemical disease with stable calcitonin levels. No patient with undetectable POCal died of the disease. In the detectable POCal group (mean age = 42.9 years, 52.8% women, median tumor size 3.0 cm [1.8-4.2 cm]; 136 [70.5%] had lymph node metastasis and 63 [32.6%] had distant metastasis), 18 (9.2%) patients achieved disease-free status, 51 (26.6%) had biochemical disease, and 61 (31.6%) had persistent structural disease. Sixty-three (32.6%) patients died of disease-related events. Further analysis using a multivariate model identified undetectable POCal as an independent prognostic variable for disease-free status (HR = 5.33, CI = 2.86-9.94; p < 0.001). Conclusions: POCal is a strong prognostic marker for long-term disease-free survival and might help define follow-up strategies for MTC patients.
引用
- Duval MADS, Ferreira CV, Marmitt L, et al. An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study. Thyroid. 2022. PMID: 36222615. doi:10.1089/thy.2022.0295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。